It is currently FDA-approved for treating metastatic non-small cell lung cancer with ALK or ROS-1 positivity per an FDA-approved test, ALK-positive anaplastic large cell lymphoma, and ALK-positive inflammatory myofibroblastic tumors. Here, ALK is linked to non-small cell lung carcinoma.